Company: CSDX
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001214659-25-016410
Chunk: 12

Company: CS DIAGNOSTICS CORP.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 12
---
 and development,
salaries and rent;

- changes in supply of or demand for similar or competing products;

- the impact of changes in regulation;

- earthquakes and other natural disasters, terrorist acts, civil
disturbances or acts of war which may result in uninsured or underinsured losses; and

- changes in tax policy.

Our future revenue and reputation may be affected by litigation
or other liability claims.

We have not procured a general liability insurance policy for our business.
To the extent that we suffer a loss of a type which would normally be covered by general liability, we would incur significant expenses
in defending any action against us and in paying any claims that result from a settlement or judgment against us. Adverse publicity could
result in a loss of consumer confidence in our products.

As we increase operations, our earnings may be sensitive to fluctuations
in market prices and demand for our products and services.

In addition, after we commence operations, the demand for our pharmaceutical
products could decline, whether because of supply or for any other reason, including competing products considered to be superior by end
users. A decrease in the selling price received for our products or a decline in demand for our products after we commence operations
could have a material adverse effect on our business, results of operations and financial condition

We have limited marketing capability.

We have limited marketing capabilities and resources. In order to achieve
market penetration we will have to undertake significant efforts and expenditures to create awareness of, and demand for, our products
and services. Our ability to penetrate the market and build our customer base will be substantially dependent on our marketing efforts.
Our failure to successfully develop our marketing capabilities, both internally and through third-party alliances, would have a material
adverse effect on our business, operating results and financial condition. Further, there can be no assurance that, if developed, such
marketing capabilities will lead to sales of our products and services.

  16  

Our investments in product research and development may not yield
anticipated returns, which would harm our operating results and reduce the amount of funds available for distributions.

A key component of our growth strategy is exploring new and innovative
pharmaceutical products through strategic acquisition, licensing and joint ventures. To the extent that we engage in these development
and redevelopment activities, they will be subject to the following risks normally associated with these projects:

- we may be unable to obtain financing for these projects on favorable
terms or at all;

- we may not complete development projects on schedule or within
budgeted amounts